ImmunoPrecise Antibodies Ltd (IPA) - רווח למניה בשנים עשר החודשים האחרונים

ImmunoPrecise Antibodies (IPA) is valued by partners for its advanced AI-driven antibody discovery platforms. The business maintains high macro-resilience, supported by the long-term budgets of pharmaceutical behemoths. The rolling net income per share chart visualizes this balance, where -0.67 serves as the current parameter value. However, rising interest rates may slow the influx of new contracts, leaving the company moderately dependent on market cycles.

For the biotech leader ImmunoPrecise Antibodies (IPA), which utilizes AI in antibody development, the monetization of intellectual property is critical. This metric measures the final net income allocated per common share over a trailing twelve-month period. By analyzing the trailing twelve-month earnings per share, an investor can see the actual business efficiency net of all expenses. Daily recalculations of this metric promptly capture shifts in the issuer's financial stability, allowing for an objective assessment of the company's capitalization.